Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 1/20 | 0.42 |
| ▸ | ASGR1 | P07306 | 1/20 | 0.35 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.34 |
| ▸ | KDM4D | Q6B0I6 | 1/20 | 0.33 |
| ▸ | BUB1 | O43683 | 1/20 | 0.33 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.33 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.33 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.33 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.33 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
| ▸ | GABRP | O00591 | 1/20 | 0.32 |
| ▸ | GABRD | O14764 | 1/20 | 0.32 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.32 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.32 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.32 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.32 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL8054576 | 0.98 | HSD11B1 (0.41) | HSD11B1ASGR1CHRM1KDM4DBUB1 | |
| Hydrochloric Acid SCHEMBL18824762 | 0.98 | HSD11B1 (0.41) | HSD11B1ASGR1CHRM1KDM4DBUB1 | |
| SCHEMBL22233461 | 0.94 | HSD11B1 (0.39) | HSD11B1ASGR1CHRM1KDM4DBUB1 | |
| Carbamic Acid SCHEMBL28171803 | 0.94 | HSD11B1 (0.39) | HSD11B1ASGR1CHRM1KDM4DBUB1 | |
| Trifluoroacetic Acid SCHEMBL27848426 | 0.91 | HSD11B1 (0.38) | HSD11B1ASGR1BUB1SLC6A4SLC6A2 | |
| SCHEMBL181909 | 0.90 | SLC6A4 (0.42) | HSD11B1SLC6A4SLC6A2SLC6A3KCNH2 | |
| SCHEMBL1033810 | 0.90 | SLC6A4 (0.42) | HSD11B1SLC6A4SLC6A2SLC6A3KCNH2 | |
| SCHEMBL65492 | 0.90 | SLC6A4 (0.42) | HSD11B1SLC6A4SLC6A2SLC6A3KCNH2 | |
| SCHEMBL31544805 | 0.88 | HSD11B1 (0.34) | HSD11B1ASGR1CHRM1SLC6A4SLC6A2 | |
| SCHEMBL30815080 | 0.88 | HSD11B1 (0.34) | HSD11B1ASGR1CHRM1SLC6A4SLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1218 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115160300-A | Coumarin compound, preparation method thereof and application of coumarin compound in resisting Alzheimer disease | 中国人民解放军北部战区总医院 | 2022-10-11 | — | — | CN | claimed |
| US-20190233390-A1 | NOVEL PIPERIDINE CARBOXAMIDE COMPOUND, PREPARATION METHOD, AND USE THEREOF | Institute of Pharmacology and Toxicology Academy of Millitary Medical Sciences P.L.A. China (CN) | 2019-08-01 | — | — | US | claimed |
| EP-3085700-B1 | NOVEL PIPERIDINE CARBOXAMIDE COMPOUND, PREPARATION METHOD, AND USAGE THEREOF | INST PHARMACOLOGY & TOXICOLOGY ACADEMY MILITARY MEDICAL SCIENCES PLA CHINA (CN) | 2018-10-31 | — | — | EP | claimed |
| US-20180044321-A1 | NOVEL PIPERIDINE CARBOXAMIDE COMPOUND, PREPARATION METHOD, AND USE THEREOF | INSTITUTE OF PHARMACOLOGY AND TOXICOLOGY ACADEMY OF MILITARY MEDICAL SCIENCES P.L.A. CHINA (CN) | 2018-02-15 | — | — | US | claimed |
| US-20160318896-A1 | NOVEL PIPERIDINE CARBOXAMIDE COMPOUND, PREPARATION METHOD, AND USAGE THEREOF | INSTITUTE OF PHARMACOLOGY AND TOXICOLOGY ACADEMY OF MILITARY MEDICAL SCIENCES P.L.A. CHINA (CN) | 2016-11-03 | — | — | US | claimed |
| EP-3085700-A1 | NOVEL PIPERIDINE CARBOXAMIDE COMPOUND, PREPARATION METHOD, AND USAGE THEREOF | Institute of Pharmacology and Toxicology Academy of Military Medical Sciences P.L.A. China (CN) | 2016-10-26 | — | — | EP | claimed |
| EP-4027995-B1 | HPK1 ANTAGONISTS AND USES THEREOF | NIMBUS SATURN INC (US) | 2026-05-27 | — | — | EP | disclosed |
| WO-2026106389-A1 | NMT INHIBITOR AND USE THEREOF | 주식회사 이노보테라퓨틱스 | 2026-05-21 | — | — | WO | disclosed |
| WO-2026102147-A1 | TETRAHYDROISOQUINOLINE HETEROBIFUNCTIONAL BCL-XL DEGRADERS | Treeline Biosciences, Inc. (US) | 2026-05-15 | — | — | WO | disclosed |
| EP-4736854-A2 | HETEROCYCLIC COMPOUNDS AS MODULATORS OF BCL6 AS LIGAND DIRECTED DEGRADERS | Bristol-Myers Squibb Company (US) | 2026-05-06 | — | — | EP | disclosed |
| US-12617782-B2 | Pyridazinones as PARP7 inhibitors | RIBON THERAPEUTICS, INC. (US) | 2026-05-05 | — | — | US | disclosed |
| WO-2026085629-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS, COMPOSITIONS COMPRISING THEM AND USES THEREOF | Université de Montréal (CA) | 2026-04-30 | — | — | WO | disclosed |
| US-20260116890-A1 | ANTI-CANCER NUCLEAR HORMONE RECEPTOR-TARGETING COMPOUNDS | NUVATION BIO INC (US) | 2026-04-30 | — | — | US | disclosed |
| WO-1996004274-A1 | AZETIDINE, PYRROLIDINE AND PIPERIDINE DERIVATIVES | MERCK SHARP & DOHME LIMITED (GB) | 1996-02-15 | — | — | WO | disclosed |
| EP-0686642-A2 | Modified guanidino and amidino thrombin inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 1995-12-13 | — | — | EP | disclosed |
| US-5420283-A | Resolution of (R)-2-benzylsuccinic acid 4-[4-(N-t-butoxycarbonylmethylamino)-piperidine] amide | PFIZER INC. (US) | 1995-05-30 | — | — | US | disclosed |
| WO-1995004043-A1 | OPTICAL RESOLUTION OF GAMMA-(4-(((1,1-DIMETHYLETHOXY)CARBONYL)METHYLAMINO)-PIPERIDINYL-1)-GAMMA-OXO-ALPHA-(PHENYLMETHYL)-BUTYNIC ACID WITH (N,S-)CYCLOHEXYL ETHYLAMINE | PFIZER INC. (US) | 1995-02-09 | — | — | WO | disclosed |
| CN-1076690-A | SULFONAMIDOCARBOXAMIDES | HOFFMANN LA ROCHE (CH) | 1993-09-29 | — | — | CN | disclosed |
| US-5214055-A | Analgesics, psychological disorders, anxiolytic agents | ADIR ET COMPAGNIE (FR) | 1993-05-25 | — | — | US | disclosed |
| US-5189045-A | Antiserotonine agent | ADIR ET COMPAGNIE (FR) | 1993-02-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180044321-A1 | NOVEL PIPERIDINE CARBOXAMIDE COMPOUND, PREPARATION METHOD, AND USE THEREOF | HSF1, HSP90AB1, HEATR1 | HSD11B1 3383/4885ASGR1 3768/4885CHRM1 4510/4885 |
| US-20160318896-A1 | NOVEL PIPERIDINE CARBOXAMIDE COMPOUND, PREPARATION METHOD, AND USAGE THEREOF | HSF1, HSP90AB1, HSP90AA1 | HSD11B1 3326/4885ASGR1 3704/4885CHRM1 4465/4885 |
| US-12617782-B2 | Pyridazinones as PARP7 inhibitors | PARP3, PARP2, PARP1 | HSD11B1 985/4885ASGR1 1718/4885CHRM1 2590/4885 |
| US-20260116890-A1 | ANTI-CANCER NUCLEAR HORMONE RECEPTOR-TARGETING COMPOUNDS | NR5A1, NR3C1, NCOR1 | HSD11B1 53/4885ASGR1 83/4885CHRM1 1831/4885 |
| US-20190233390-A1 | NOVEL PIPERIDINE CARBOXAMIDE COMPOUND, PREPARATION METHOD, AND USE THEREOF | HSF1, HSP90AB1, HEATR1 | HSD11B1 3383/4885ASGR1 3768/4885CHRM1 4510/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.